CDK3 Antibody

What is CDK3 and what are its known cellular functions?

CDK3 is a serine/threonine-protein kinase that plays a critical role in the control of the eukaryotic cell cycle. It is specifically involved in G0-G1 and G1-S cell cycle transitions. CDK3 interacts with CCNC/cyclin-C during interphase and phosphorylates several important substrates including histone H1, ATF1, RB1, and CABLES1 .

The phosphorylation of ATF1 at serine 63 by CDK3 enhances ATF1's transactivation and transcriptional activities, which promotes cell proliferation and transformation. Additionally, CDK3/cyclin-C mediated RB1 phosphorylation is required for G0-G1 transition. CDK3 also promotes G1-S transition likely by contributing to the activation of E2F1, E2F2, and E2F3 in an RB1-independent manner .

How can researchers accurately distinguish CDK3 from other CDK family members?

To distinguish CDK3 from other CDK family members, researchers should:

• Select antibodies raised against unique epitopes - Several commercial antibodies are generated against specific regions of CDK3 that have minimal homology with other CDKs. For example, antibodies targeting the N-terminal region (aa 1-250) or specific peptide sequences unique to CDK3 .

• Perform careful validation experiments:

  • Western blot with positive and negative controls

  • Test in cell lines with known CDK3 expression levels

  • Include appropriate molecular weight markers (CDK3 is observed at 40-45 kDa on Western blots)

  • Use siRNA knockdown of CDK3 as a specificity control

• Conduct comparative analysis with other CDK antibodies to ensure specificity.

• Consider protein interaction studies, as CDK3 has specific binding partners like cyclin-C that can help distinguish it from other CDKs .

What are the primary applications for CDK3 antibodies in research?

Based on the validation data from multiple sources, CDK3 antibodies have been successfully applied in:

Most published research has employed Western blotting as the primary method for studying CDK3 expression and phosphorylation states .

How does the CDK3-ATF1 signaling axis contribute to cell transformation and cancer development?

The CDK3-ATF1 signaling axis plays a crucial role in cellular transformation and cancer development through several mechanisms:

• Phosphorylation of ATF1: CDK3 specifically phosphorylates ATF1 at serine 63 in its kinase-inducible domain (KID), which enhances ATF1's transactivation activity by promoting recruitment of the coactivator CREB-binding protein (CBP)/p300 .

• Enhanced cell proliferation: Research has shown that CDK3-mediated ATF1 phosphorylation promotes cell proliferation. siRNA directed against CDK3 (si-CDK3) suppresses ATF1 activity, resulting in inhibition of proliferation and growth of human glioblastoma T98G cells in soft agar .

• Transformation properties: CDK3 enhances epidermal growth factor (EGF)-induced anchorage-independent cell transformation in JB6 Cl41 cells. Additionally, si-CDK3 suppresses Ras^G12V/cdk3/ATF1-induced foci formation in NIH3T3 cells .

• Cancer relevance: CDK3 protein expression levels are higher in human cancer cell lines and human glioblastoma tissue compared with normal brain tissue, suggesting its role in cancer development .

• Oncogenic signaling: Experimental evidence has demonstrated that the CDK3-ATF1 signaling axis cooperates with oncogenic Ras to promote cellular transformation, indicating its involvement in multiple oncogenic pathways .

The experimental evidence for this signaling axis was confirmed through foci forming assays, where NIH3T3 cells were transiently transfected with various combinations of H-Ras^G12V, CDK3, ATF1, ATF1 S63A (phosphorylation-deficient mutant), or si-CDK3 .

What approaches can be used to design effective siRNA against CDK3 for knockdown experiments?

Designing effective siRNA against CDK3 for knockdown experiments requires careful consideration of several factors:

• Target sequence selection: Based on published research, effective siRNA against CDK3 has been designed targeting specific regions. The mutations of CDK3 (408T/C, 411G/A, 412T/C, and 414G/C) have been used to generate siRNA-resistant CDK3 expression vectors for rescue experiments .

• Vector system: The pU6pro vector has been successfully used to construct si-RNA against CDK3 (si-CDK3). This approach involves:

  • Designing synthetic primers

  • Annealing the primers

  • Introducing them into the pU6pro vector digested with XbaI and BbsI

• Validation controls:

  • Include a scrambled siRNA control (si-mock) as a negative control

  • Generate rescue constructs with silent mutations to validate specificity

  • Confirm knockdown by Western blot analysis

• Experimental verification:

  • Confirm reduced CDK3 protein levels via Western blot

  • Assess functional consequences (e.g., reduced ATF1 phosphorylation)

  • Test biological effects (e.g., reduced cell proliferation or transformation)

For optimal results, researchers should target multiple regions of the CDK3 mRNA and validate knockdown efficiency with proper controls.

How does CDK3 expression differ between normal and cancer tissues, and what methodologies best demonstrate this difference?

Research has demonstrated significant differences in CDK3 expression between normal and cancer tissues:

• Expression patterns: CDK3 protein expression levels are higher in human cancer cell lines and human glioblastoma tissue compared with normal brain tissue .

• Methodological approaches to demonstrate differences:

  a. Western blot analysis:

  • Compare CDK3 protein levels in cancer cell lines (e.g., T98G, HepG2, MCF-7, Jurkat) versus normal tissues

  • Use validated antibodies at optimized dilutions (1:1000-1:4000)

  • Include proper loading controls and quantification methods

  b. Immunohistochemistry (IHC):

  • Compare normal versus tumor tissue sections

  • Use optimized antibody dilutions (1:100-1:400)

  • Apply appropriate antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Quantify staining intensity and distribution

  c. Functional validation:

  • Manipulate CDK3 levels in normal versus cancer cells

  • Assess impact on cell proliferation, transformation, and other cancer-related phenotypes

  • Use soft agar assays to measure anchorage-independent growth

• Validated specimens: The most well-documented differences have been observed in:

  • Glioblastoma versus normal brain tissue

  • Human cancer cell lines (HepG2, T98G, MCF-7, Jurkat) versus normal counterparts

These approaches collectively provide strong evidence for the differential expression of CDK3 in cancer versus normal tissues.

What are the optimal protocols for detecting CDK3 via Western blotting?

For optimal detection of CDK3 via Western blotting, researchers should follow these recommendations based on published protocols:

• Sample preparation:

  • Prepare whole cell lysates from appropriate cells (HepG2, MCF-7, Jurkat, T98G, U87-MG, U251, HEK293T, Raw264.7, PC12)

  • Use standard lysis buffers containing protease and phosphatase inhibitors

• Gel electrophoresis:

  • Use 10% SDS-PAGE for optimal separation

  • Load 30 μg of protein per lane

• Antibody selection and dilution:

  • Primary antibody: Use validated anti-CDK3 antibodies at dilutions of 1:1000-1:4000

  • Secondary antibody: Use appropriate HRP-conjugated secondary antibodies

• Detection:

  • CDK3 appears at approximately 40-45 kDa on Western blots

  • Use ECL or other appropriate detection methods

• Controls:

  • Positive controls: HepG2, MCF-7, Jurkat cells

  • Loading controls: Standard housekeeping proteins (β-actin, GAPDH)

  • Specificity control: siRNA-mediated knockdown of CDK3

Example protocol from validated studies:

• 10% SDS-PAGE

• Transfer to PVDF membrane

• Block with 5% non-fat milk

• Incubate with anti-CDK3 antibody (1:1000 dilution) overnight at 4°C

• Wash with TBST buffer

• Incubate with HRP-conjugated secondary antibody

• Develop using ECL substrate

How can proximity ligation assays be used to study CDK3 interactions with binding partners?

Proximity ligation assay (PLA) is a powerful technique for studying CDK3 interactions with binding partners at the endogenous level. Based on published research, here's how to implement this approach:

• Principle and advantages:

  • Detects protein-protein interactions with high specificity

  • Enables visualization of interactions in situ

  • Can detect endogenous protein interactions without overexpression

  • Produces fluorescent signals only when proteins are within 40 nm of each other

• Methodology for CDK3 interactions:

  • Cell preparation: Culture cells on coverslips and fix with appropriate fixative

  • Primary antibodies: Use anti-CDK3 antibody and antibody against potential interacting protein (e.g., PTP1B, cyclins) raised in different species

  • PLA probes: Incubate with species-specific secondary antibodies conjugated to oligonucleotides

  • Ligation and amplification: Add DNA ligase and polymerase to form and amplify circular DNA

  • Detection: Hybridize with fluorescent complementary oligonucleotides and visualize under fluorescence microscope

• Validated applications for CDK3:

  • CDK3-PTP1B interactions have been successfully detected in glioblastoma cell lines (LN229, U87-MG, and U251)

  • Multiple interaction loci were observed in both cytoplasm and nucleus

• Controls and validation:

  • Negative controls: Omission of one primary antibody

  • Positive controls: Known interacting partners

  • Validation: Confirm interactions by co-immunoprecipitation

This approach has successfully demonstrated the interaction between endogenous PTP1B and CDK3 in multiple glioblastoma cell lines, revealing interaction sites in both cytoplasmic and nuclear compartments .

Validating the specificity of CDK3 antibodies is crucial for reliable research outcomes. Based on established practices in the field, here's a comprehensive approach:

• Western blot analysis:

  • Test across multiple cell lines with known CDK3 expression (HepG2, T98G, MCF-7)

  • Verify single band at expected molecular weight (40-45 kDa)

  • Compare with positive control cell lines

• Knockdown/knockout validation:

  • Perform siRNA-mediated knockdown of CDK3

  • Compare antibody signal in control versus knockdown samples

  • Use rescue experiments with CDK3 expression constructs to confirm specificity

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be blocked or significantly reduced

  • Include non-competing peptide as negative control

• Cross-reactivity assessment:

  • Test against recombinant CDK family members

  • Examine potential cross-reactivity with closely related proteins

  • Use protein arrays to test broader specificity (e.g., arrays of 364 human recombinant protein fragments)

• Immunoprecipitation followed by mass spectrometry:

  • Perform IP with the CDK3 antibody

  • Analyze pulled-down proteins by mass spectrometry

  • Confirm presence of CDK3 and known interacting partners

• Multi-antibody concordance:

  • Compare results using multiple antibodies targeting different epitopes of CDK3

  • Consistent results across antibodies increase confidence in specificity

These validation steps ensure that the observed signals are truly representative of CDK3 protein and not due to cross-reactivity with other proteins.

What experimental approaches can validate the role of CDK3 in cellular transformation?

Several experimental approaches have been validated to assess CDK3's role in cellular transformation:

• Soft agar colony formation assay:

  • Researchers have demonstrated that siRNA against CDK3 suppresses growth of human glioblastoma T98G cells in soft agar

  • This assay measures anchorage-independent growth, a hallmark of transformed cells

• Foci formation assay:

  • NIH3T3 cells can be transfected with various combinations of:

    • H-Ras^G12V (100 ng)

    • CDK3 (500 ng)

    • ATF1 (500 ng)

    • ATF1 S63A (500 ng, phosphorylation-deficient mutant)

    • si-CDK3 (500 ng)

  • After 2 weeks of culture in 5% calf serum/DMEM, foci are fixed with methanol, stained with 0.5% crystal violet, and counted

  • This approach has shown that si-CDK3 suppresses Ras^G12V/CDK3/ATF1-induced foci formation

• EGF-induced transformation assay:

  • Using JB6 Cl41 cells, researchers have shown that CDK3 enhances EGF-induced transformation

  • This model is particularly useful for studying promotion-sensitive cellular transformation

• Molecular signaling analysis:

  • Phosphorylation of ATF1 at serine 63 by CDK3 can be monitored by:

    • Phospho-specific antibodies

    • Kinase assays with wild-type and mutant (S63A) ATF1

  • This approach links CDK3 kinase activity to downstream signaling events in transformation

• In vivo tumorigenesis assays:

  • Cells with modulated CDK3 expression can be injected into nude mice to assess tumor formation potential

  • Knockdown of ATF1 has been shown to suppress tumorigenicity and metastatic potential in nude mice, suggesting a similar approach could be valuable for CDK3

These complementary approaches provide robust validation of CDK3's role in cellular transformation across multiple experimental systems.

How can researchers accurately assess CDK3 kinase activity in experimental systems?

Accurately assessing CDK3 kinase activity requires specific methodological approaches:

• In vitro kinase assays:

  • Immunoprecipitation: Isolate CDK3 using specific antibodies from cell lysates

  • Substrate selection: Use known CDK3 substrates (ATF1, histone H1, RB1, CABLES1)

  • Reaction conditions: Incubate with substrates in the presence of [γ-32P]ATP or non-radioactive ATP

  • Detection: Analyze by autoradiography or phospho-specific antibodies

  • Controls: Include kinase-dead CDK3 mutants as negative controls

• Phospho-specific antibody detection:

  • Direct assessment: Use phospho-specific antibodies against CDK3 substrates (e.g., ATF1 phospho-Ser63)

  • Western blotting: Monitor changes in substrate phosphorylation states

  • Validation: Compare phosphorylation in CDK3 overexpression vs. knockdown conditions

• Cellular reporter systems:

  • ATF1 transcriptional activity: Use reporter constructs with ATF1 binding sites

  • Phosphorylation-dependent interactions: Monitor CDK3-dependent protein interactions

  • Cell cycle progression: Assess G0-G1 and G1-S transitions as functional readouts of CDK3 activity

• Cyclin binding and activation:

  • Co-immunoprecipitation: Analyze CDK3 interaction with cyclins (particularly cyclin-C)

  • CDK3/cyclin complex isolation: Purify active complexes for activity measurements

  • Cell cycle phase correlation: Compare activity across different cell cycle phases

• Inhibitor studies:

  • Chemical inhibitors: Assess effects of CDK inhibitors on CDK3 activity

  • Specificity controls: Include related CDKs to establish selectivity

  • Dose-response relationships: Determine IC50 values for inhibition

These approaches, particularly when used in combination, provide robust assessment of CDK3 kinase activity in experimental systems.

What are common challenges in CDK3 antibody experiments and how can they be addressed?

Researchers working with CDK3 antibodies may encounter several challenges:

• Weak or nonspecific signals in Western blotting:

  • Solution: Optimize antibody concentration (try 1:500-1:4000 dilution range)

  • Solution: Extend primary antibody incubation (overnight at 4°C)

  • Solution: Use enhanced chemiluminescence substrates for detection

  • Solution: Increase protein loading (30 μg recommended)

• Cross-reactivity with other CDK family members:

  • Solution: Select antibodies raised against unique regions of CDK3

  • Solution: Validate with siRNA knockdown of CDK3

  • Solution: Confirm results with multiple antibodies targeting different epitopes

  • Solution: Include appropriate positive and negative controls

• Variable expression levels across cell lines:

  • Solution: Use validated cell lines with confirmed CDK3 expression (HepG2, MCF-7, Jurkat, T98G)

  • Solution: Consider tissue-specific expression patterns

  • Solution: Normalize to appropriate housekeeping proteins

• Challenges in detecting phosphorylated substrates:

  • Solution: Use phospho-specific antibodies for key substrates (e.g., ATF1 phospho-Ser63)

  • Solution: Include phosphatase inhibitors in lysis buffers

  • Solution: Compare samples with and without CDK3 inhibition or knockdown

• Inconsistent IHC/IF staining:

  • Solution: Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Solution: Test different fixation methods

  • Solution: Adjust antibody concentration (1:50-1:400 for IHC, 1:200-1:800 for IF)

• Difficulties in co-immunoprecipitation experiments:

  • Solution: Use mild lysis conditions to preserve protein interactions

  • Solution: Consider cross-linking to stabilize transient interactions

  • Solution: Verify interaction with proximity ligation assay

By implementing these solutions, researchers can significantly improve the reliability and reproducibility of their CDK3 antibody experiments.

What controls should be included in experiments investigating CDK3 function and expression?

When investigating CDK3 function and expression, the following controls are essential for rigorous and reproducible research:

• Antibody specificity controls:

  • Positive controls: Cell lines with known CDK3 expression (HepG2, MCF-7, Jurkat, T98G)

  • Negative controls: CDK3 knockdown or knockout samples

  • Peptide competition: Pre-incubation of antibody with immunizing peptide

  • Secondary antibody only: To assess background signal

• Expression manipulation controls:

  • Empty vector: For overexpression studies

  • Scrambled siRNA (si-mock): For knockdown experiments

  • Rescue experiments: CDK3 re-expression in knockdown cells using siRNA-resistant constructs

  • Dose dependency: Multiple levels of expression or knockdown

• Functional/activity controls:

  • Kinase-dead mutants: For enzymatic activity studies

  • Phospho-deficient substrates: e.g., ATF1 S63A mutant

  • Cell cycle synchronization: To control for cell cycle effects

  • Inhibitor controls: Specific CDK inhibitors versus broad-spectrum kinase inhibitors

• Experimental technique controls:

  • Loading controls: Housekeeping proteins (β-actin, GAPDH) for Western blots

  • IHC/IF controls: Isotype controls, known positive and negative tissues

  • IP controls: IgG control, input samples (5-10% of lysate)

  • Proximity ligation controls: Single antibody controls, known interacting proteins

• Biological response controls:

  • Cell proliferation: Positive and negative regulators

  • Cell transformation: Known oncogenes (e.g., Ras^G12V) and tumor suppressors

  • In vivo studies: Vehicle control, positive control treatments

Including these comprehensive controls significantly enhances the reliability and interpretability of experiments investigating CDK3 function and expression.

What are emerging areas of CDK3 research that could benefit from improved antibody-based methodologies?

Several emerging research areas could benefit from improved CDK3 antibody methodologies:

• Single-cell analysis of CDK3 expression and activity:

  • Development of highly sensitive antibodies for low-abundance detection

  • Compatibility with single-cell proteomics and phosphoproteomics

  • Integration with spatial transcriptomics data

• CDK3 as a therapeutic target in cancer:

  • Antibodies for patient stratification based on CDK3 expression

  • Monitoring response to CDK inhibitors in clinical samples

  • Developing CDK3-specific inhibitors through structural studies

• PTP1B-CDK3 signaling axis in cancer progression:

  • Improved proximity ligation assays to map interaction domains

  • Antibodies to detect specific phosphorylation states of CDK3

  • Methods to assess activation mechanisms independent of CDC25

• CDK3 in cell cycle regulation beyond G0-G1 and G1-S transitions:

  • Phase-specific antibodies to track CDK3 localization throughout the cell cycle

  • Improved immunofluorescence protocols for co-localization studies

  • Phospho-specific antibodies for cell cycle-dependent substrates

• Development of CDK3 biomarkers for cancer prognosis:

  • Standardized IHC protocols for clinical sample analysis

  • Multiplex immunofluorescence to assess CDK3 and substrate activation

  • Correlation with patient outcomes in various cancer types

These emerging areas will require continued refinement of antibody technologies, including:

• Higher specificity antibodies distinguishing CDK3 from other CDK family members

• Improved phospho-specific antibodies for key substrates

• Compatible protocols for clinical samples and advanced imaging techniques

• Antibody formats suitable for multiplexed detection systems

Advancing these methodologies will accelerate our understanding of CDK3's roles in normal physiology and disease pathogenesis.

How might rapid antibody discovery technologies improve CDK3-focused research?

Recent advances in rapid antibody discovery technologies offer significant potential to improve CDK3-focused research:

• Microfluidics-enabled antibody discovery:

  • Recent technology has demonstrated rapid discovery of monoclonal antibodies by screening millions of mouse and human antibody-secreting cells (ASCs)

  • This approach has yielded antibodies with extraordinarily high affinity (<1 pM) and functionality in just 2 weeks

  • Applied to CDK3 research, this could generate highly specific antibodies targeting unique epitopes or post-translational modifications

• Benefits for CDK3 research:

  • Higher specificity: Improved distinction between CDK3 and other CDK family members

  • Post-translational modification detection: Better antibodies against specific phosphorylation states

  • Expanded application range: Antibodies optimized for multiple techniques (WB, IHC, IF, IP)

  • Increased sensitivity: Detection of lower abundance CDK3 in primary tissues

• Potential applications:

  • Conformational antibodies: Detecting active versus inactive CDK3 states

  • Interaction-specific antibodies: Recognizing CDK3-cyclin complexes

  • Species-specific variants: Better tools for animal models

  • Therapeutic development: Potential for CDK3-targeting biologics

• Integration with other technologies:

  • Combination with CRISPR screens to validate CDK3 pathways

  • Pairing with proteomics to discover new CDK3 substrates

  • Application in high-content imaging for pathway analysis

  • Development of biosensors for real-time CDK3 activity monitoring

The high hit rates (>85% binding) and rapid development timeline (2 weeks) offered by these new technologies could significantly accelerate CDK3 research by providing more precise tools for investigating its diverse cellular functions and potential as a therapeutic target .

By facilitating access to the underexplored antibody-secreting cell compartment, these approaches enable more efficient antibody discovery and could drive new immunological studies into CDK3's roles in cell cycle regulation and cancer progression .